IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses

Meryem Aloulou, Sanae Ben Mkaddem, Martine Biarnes-Pelicot, Tarek Boussetta, Hervé Souchet, Elisabetta Rossato, Marc Benhamou, Bruno Crestani, Zhou Zhu, Ulrich Blank, Pierre Launay, Renato C. Monteiro

Research output: Contribution to journalArticle

Abstract

Intravenous immunoglobulin (IVIg) has been used in the treatment of several autoimmune and inflammatory diseases. However, its mechanism of action remains incompletely understood. Here, we investigated the possibility that IVIg induces its anti-inflammatory effects through activating Fcγ receptors bearing an immunoreceptor tyrosine-based activation motif (ITAM) in the FcRγ signaling adaptor. Recently, the concept of inhibitory ITAM (ITAMi) has emerged as a new means to negatively control the immune response. We found that interaction of FcRγ-associated mouse or human FcγRIII with uncomplexed IgG1 or IVIg, or with bivalent anti-FcγRIII F(ab′) 2 reduced calcium responses, reactive oxygen species production, endocytosis, and phagocytosis, induced by heterologous activating receptors on monocyte/macrophages and FcγRIII+ transfectants. Inhibition required the ITAMi configuration of the FcγRIII-associated FcRγ subunit and SHP-1 recruitment involving formation of intracellular "inhibisome" clusters containing FcγRIII, and the targeted heterologous activating receptor. IVIg as well as anti-FcγRIII treatments controlled the development of nonimmune mediated inflammation in vivo independently of FcγRIIB. These results demonstrate that circulating immunoglobulins (Ig)Gs are not functionally inert but act through continuous interaction with FcγRIII-inducing ITAMi signaling to maintain immune homeostasis. These data support a new mechanism of action for IVIg and demonstrate the therapeutic potential of FcγRIIIA targeting in inflammation.

Original languageEnglish (US)
Pages (from-to)3084-3096
Number of pages13
JournalBlood
Volume119
Issue number13
DOIs
StatePublished - Mar 29 2012

Fingerprint

Immunoreceptor Tyrosine-Based Activation Motif
Intravenous Immunoglobulins
Tyrosine
Immunoglobulin G
Chemical activation
Bearings (structural)
Inflammation
Fc Receptors
Macrophages
Endocytosis
Phagocytosis
Autoimmune Diseases
Immunoglobulins
Monocytes
Reactive Oxygen Species
Homeostasis
Anti-Inflammatory Agents
Calcium

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Aloulou, M., Mkaddem, S. B., Biarnes-Pelicot, M., Boussetta, T., Souchet, H., Rossato, E., ... Monteiro, R. C. (2012). IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. Blood, 119(13), 3084-3096. https://doi.org/10.1182/blood-2011-08-376046

IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. / Aloulou, Meryem; Mkaddem, Sanae Ben; Biarnes-Pelicot, Martine; Boussetta, Tarek; Souchet, Hervé; Rossato, Elisabetta; Benhamou, Marc; Crestani, Bruno; Zhu, Zhou; Blank, Ulrich; Launay, Pierre; Monteiro, Renato C.

In: Blood, Vol. 119, No. 13, 29.03.2012, p. 3084-3096.

Research output: Contribution to journalArticle

Aloulou, M, Mkaddem, SB, Biarnes-Pelicot, M, Boussetta, T, Souchet, H, Rossato, E, Benhamou, M, Crestani, B, Zhu, Z, Blank, U, Launay, P & Monteiro, RC 2012, 'IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses', Blood, vol. 119, no. 13, pp. 3084-3096. https://doi.org/10.1182/blood-2011-08-376046
Aloulou M, Mkaddem SB, Biarnes-Pelicot M, Boussetta T, Souchet H, Rossato E et al. IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. Blood. 2012 Mar 29;119(13):3084-3096. https://doi.org/10.1182/blood-2011-08-376046
Aloulou, Meryem ; Mkaddem, Sanae Ben ; Biarnes-Pelicot, Martine ; Boussetta, Tarek ; Souchet, Hervé ; Rossato, Elisabetta ; Benhamou, Marc ; Crestani, Bruno ; Zhu, Zhou ; Blank, Ulrich ; Launay, Pierre ; Monteiro, Renato C. / IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses. In: Blood. 2012 ; Vol. 119, No. 13. pp. 3084-3096.
@article{57f7e13e8c7d47158e6d628ee27fb9e0,
title = "IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses",
abstract = "Intravenous immunoglobulin (IVIg) has been used in the treatment of several autoimmune and inflammatory diseases. However, its mechanism of action remains incompletely understood. Here, we investigated the possibility that IVIg induces its anti-inflammatory effects through activating Fcγ receptors bearing an immunoreceptor tyrosine-based activation motif (ITAM) in the FcRγ signaling adaptor. Recently, the concept of inhibitory ITAM (ITAMi) has emerged as a new means to negatively control the immune response. We found that interaction of FcRγ-associated mouse or human FcγRIII with uncomplexed IgG1 or IVIg, or with bivalent anti-FcγRIII F(ab′) 2 reduced calcium responses, reactive oxygen species production, endocytosis, and phagocytosis, induced by heterologous activating receptors on monocyte/macrophages and FcγRIII+ transfectants. Inhibition required the ITAMi configuration of the FcγRIII-associated FcRγ subunit and SHP-1 recruitment involving formation of intracellular {"}inhibisome{"} clusters containing FcγRIII, and the targeted heterologous activating receptor. IVIg as well as anti-FcγRIII treatments controlled the development of nonimmune mediated inflammation in vivo independently of FcγRIIB. These results demonstrate that circulating immunoglobulins (Ig)Gs are not functionally inert but act through continuous interaction with FcγRIII-inducing ITAMi signaling to maintain immune homeostasis. These data support a new mechanism of action for IVIg and demonstrate the therapeutic potential of FcγRIIIA targeting in inflammation.",
author = "Meryem Aloulou and Mkaddem, {Sanae Ben} and Martine Biarnes-Pelicot and Tarek Boussetta and Herv{\'e} Souchet and Elisabetta Rossato and Marc Benhamou and Bruno Crestani and Zhou Zhu and Ulrich Blank and Pierre Launay and Monteiro, {Renato C.}",
year = "2012",
month = "3",
day = "29",
doi = "10.1182/blood-2011-08-376046",
language = "English (US)",
volume = "119",
pages = "3084--3096",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "13",

}

TY - JOUR

T1 - IgG1 and IVIg induce inhibitory ITAM signaling through FcγRIII controlling inflammatory responses

AU - Aloulou, Meryem

AU - Mkaddem, Sanae Ben

AU - Biarnes-Pelicot, Martine

AU - Boussetta, Tarek

AU - Souchet, Hervé

AU - Rossato, Elisabetta

AU - Benhamou, Marc

AU - Crestani, Bruno

AU - Zhu, Zhou

AU - Blank, Ulrich

AU - Launay, Pierre

AU - Monteiro, Renato C.

PY - 2012/3/29

Y1 - 2012/3/29

N2 - Intravenous immunoglobulin (IVIg) has been used in the treatment of several autoimmune and inflammatory diseases. However, its mechanism of action remains incompletely understood. Here, we investigated the possibility that IVIg induces its anti-inflammatory effects through activating Fcγ receptors bearing an immunoreceptor tyrosine-based activation motif (ITAM) in the FcRγ signaling adaptor. Recently, the concept of inhibitory ITAM (ITAMi) has emerged as a new means to negatively control the immune response. We found that interaction of FcRγ-associated mouse or human FcγRIII with uncomplexed IgG1 or IVIg, or with bivalent anti-FcγRIII F(ab′) 2 reduced calcium responses, reactive oxygen species production, endocytosis, and phagocytosis, induced by heterologous activating receptors on monocyte/macrophages and FcγRIII+ transfectants. Inhibition required the ITAMi configuration of the FcγRIII-associated FcRγ subunit and SHP-1 recruitment involving formation of intracellular "inhibisome" clusters containing FcγRIII, and the targeted heterologous activating receptor. IVIg as well as anti-FcγRIII treatments controlled the development of nonimmune mediated inflammation in vivo independently of FcγRIIB. These results demonstrate that circulating immunoglobulins (Ig)Gs are not functionally inert but act through continuous interaction with FcγRIII-inducing ITAMi signaling to maintain immune homeostasis. These data support a new mechanism of action for IVIg and demonstrate the therapeutic potential of FcγRIIIA targeting in inflammation.

AB - Intravenous immunoglobulin (IVIg) has been used in the treatment of several autoimmune and inflammatory diseases. However, its mechanism of action remains incompletely understood. Here, we investigated the possibility that IVIg induces its anti-inflammatory effects through activating Fcγ receptors bearing an immunoreceptor tyrosine-based activation motif (ITAM) in the FcRγ signaling adaptor. Recently, the concept of inhibitory ITAM (ITAMi) has emerged as a new means to negatively control the immune response. We found that interaction of FcRγ-associated mouse or human FcγRIII with uncomplexed IgG1 or IVIg, or with bivalent anti-FcγRIII F(ab′) 2 reduced calcium responses, reactive oxygen species production, endocytosis, and phagocytosis, induced by heterologous activating receptors on monocyte/macrophages and FcγRIII+ transfectants. Inhibition required the ITAMi configuration of the FcγRIII-associated FcRγ subunit and SHP-1 recruitment involving formation of intracellular "inhibisome" clusters containing FcγRIII, and the targeted heterologous activating receptor. IVIg as well as anti-FcγRIII treatments controlled the development of nonimmune mediated inflammation in vivo independently of FcγRIIB. These results demonstrate that circulating immunoglobulins (Ig)Gs are not functionally inert but act through continuous interaction with FcγRIII-inducing ITAMi signaling to maintain immune homeostasis. These data support a new mechanism of action for IVIg and demonstrate the therapeutic potential of FcγRIIIA targeting in inflammation.

UR - http://www.scopus.com/inward/record.url?scp=84859364858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859364858&partnerID=8YFLogxK

U2 - 10.1182/blood-2011-08-376046

DO - 10.1182/blood-2011-08-376046

M3 - Article

C2 - 22337713

AN - SCOPUS:84859364858

VL - 119

SP - 3084

EP - 3096

JO - Blood

JF - Blood

SN - 0006-4971

IS - 13

ER -